文献速递衰弱、肌少症与跌倒老年慢病共病管理

细胞周期阻滞:老年癌症患者支持治疗的突破

Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.
PubMed 文献 · J Am Geriatr Soc · 2023-04-10

本文综述了Trilaciclib和ALRN-6924通过诱导正常细胞暂时性细胞周期阻滞(CCA)来预防化疗毒性的研究进展。ALRN-6924在随机对照研究中未显示显著活性,开发暂停。

要点

  • Trilaciclib在RB1基因非 proficient 的非小细胞肺癌患者中预防 neutropenia、血小板减少和贫血有效。
  • ALRN-6924在随机对照研究中未显示显著活性,开发暂停。

核心结论

  • CCA是一种针对化疗毒性的新型 proactive 方法,对老年患者特别有意义。
  • CCA至少可能通过单药预防所有形式的骨髓毒性,避免多药治疗的风险和成本。
  • CCA可能允许 frail 患者接受全剂量化疗。

研究设计与样本

  • 综述了Medline上相关出版物、已发表的药物信息及主要医学会议报告。
  • Trilaciclib证据来自三项随机对照II期试验。
  • ALRN-6924证据来自一项随机对照研究。

主要发现

  • Trilaciclib在RB1基因非 proficient 的非小细胞肺癌患者中预防 neutropenia、血小板减少和贫血有效。
  • ALRN-6924在TP53缺失或突变的癌症患者中预防骨髓毒性曾显示前景,但在随机对照研究中未显示显著活性。

关键数值与推荐

  • Trilaciclib获FDA批准用于管理RB1基因非 proficient 的非小细胞肺癌患者的化疗毒性。
  • ALRN-6924开发目前暂停。

临床怎么用

  • CCA可能通过单药预防骨髓毒性,避免多药治疗的风险和成本。
  • CCA可避免骨髓造血生长因子的并发症,包括严重疼痛、干细胞竞争、骨髓耗竭和血液恶性肿瘤。
  • CCA可能允许 frail 患者接受全剂量化疗。
  • 合理预期CCA可能预防口腔炎、食管炎、腹泻和脱水等常见且有时致命的化疗并发症。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age is a major risk factor for the acute and chronic complications of cancer chemotherapy. The current approach to the prevention of these complications is reactive and involves the reduction of the doses and the delay of treatment which may compromise the outcome. There is a limited number of antidotes to chemotherapy toxicity and these have complications of their own. Oldest old and frail patients are mostly excluded from life saving cancer treatment due to the risk of severe and even lethal complications. METHODS: molecular biology has revealed that different checkpoints control the proliferative cycle of normal and neoplastic cells. Two new drugs, Trilaciclib and ALRN-6924 may cause a temporary cell cycle arrest (CCA) of normal cells without blocking the proliferation of the neoplastic ones and render the normal cells temporarily invulnerable to the toxicity of chemotherapy. We reviewed the publications related to these drugs on the Medline, the published drug information and the presentations to major medical conferences. RESULTS: In three randomized controlled phase II trials Trilaciclib proved effective in preventing neutropenia, thrombocytopenia and anemia in patients with non small cell lung cancer with non proficient RB1 gene. Forty-five percent of patients were 65 and older and age did not prevent the effectiveness of the drug. Trilaciclib was approved by the FDA for the management of these patients. ALRN-6924 appeared promising in preventing myelotoxicity in patients whose cancer had deleted or mutated TP53, but failed to show any significant activity in a randomized controlled study. The development of this drug is now on hold CONCLUSIONS: CCA is a novel proactive approach to the toxicity of chemotherapy of special interest to older patients. At the very least it may prevent all forms of myelotoxicity with a single agent, obviating the risk and cost of polypharmacy. It allows to avoid the complications of myelopoietic growth factors which include severe pain, stem cell competition, bone marrow exhaustion, and hematological malignancies. It may allow the treatment of frail patients with full chemotherapy doses. It is also reasonable to expect that may complications other common and sometimes lethal complications of chemotherapy such as stomatitis, esophagitis, diarrhea and dehydration.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Falandry C, List A, Balducci L, et al. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients. J Am Geriatr Soc. 2023. PMID: 37036091. doi:10.1111/jgs.18350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。